Valuation: Novacyt

Market Cap 3.25Cr 3.69Cr 3.02Cr 2.77Cr 5.2Cr 357.45Cr 5.29Cr 36Cr 14Cr 174.35Cr 14Cr 14Cr 604.86Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 3.44Cr 3.91Cr 3.2Cr 2.94Cr 5.51Cr 378.98Cr 5.61Cr 38Cr 15Cr 184.85Cr 15Cr 14Cr 641.31Cr EV / Sales 2026 *
1.13x
EV / Sales 2027 * 1.07x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day+1.05%
1 week+3.80%
Current month+14.78%
1 month+20.00%
3 months+24.92%
6 months+13.47%
Current year+11.71%
1 week 36.4
Extreme 36.4
41.6
1 month 33
Extreme 33
46.2
Current year 26.6
Extreme 26.6
86
1 year 26.6
Extreme 26.6
86
3 years 26.6
Extreme 26.6
137
5 years 26.6
Extreme 26.6
497.3
10 years 6.03
Extreme 6.03
1,270
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
+4.21%+3.80% - - 3.71Cr
-0.96%-5.87%-39.83%-44.10% 62Cr
-0.82%-8.55%+195.92% - 53Cr
+6.70%-5.78%-38.66%+7.40% 11Cr
+0.39%-2.62%+7.00%+57.58% 9.93Cr
Average +1.30%-1.47%+31.11%+6.96% 33.8Cr
Weighted average by Cap. -0.12%-1.15%+55.38%-25.28%

Financials

2026 *2027 *
Net sales 3.05Cr 3.47Cr 2.84Cr 2.61Cr 4.89Cr 336.11Cr 4.98Cr 34Cr 13Cr 163.94Cr 13Cr 13Cr 568.76Cr 3.49Cr 3.96Cr 3.24Cr 2.98Cr 5.59Cr 383.85Cr 5.69Cr 39Cr 15Cr 187.23Cr 15Cr 15Cr 649.55Cr
Net income - -
Net Debt 19.56L 22.24L 18.17L 16.71L 31.34L 22Cr 31.9L 2.17Cr 84.75L 11Cr 83.49L 81.69L 36Cr 48.42L 55.05L 44.98L 41.37L 77.58L 53Cr 78.97L 5.38Cr 2.1Cr 26Cr 2.07Cr 2.02Cr 90Cr
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
23/26/23 GBX 39.60 +4.21% 1,772
22/26/22 GBX 38.00 0.00% 17,940
21/26/21 GBX 38.00 -8.65% 62,872
20/26/20 GBX 41.60 +4.00% 1,36,774
17/26/17 GBX 40.00 +4.85% 93,837

Annual profits - Rate of surprise